Document is current

Article History

Received: 27 May 2024

Accepted: 3 July 2024

First Online: 15 July 2024

Declarations

:

: H.-F.L. and S.G. are employees of Pfizer. Y.K. has received lecturer honoraria from Sanofi, AbbVie, Pfizer, and Maruho and research funding from Sanofi, Leo Pharma, Pfizer, Maruho, Lilly, AbbVie, Otsuka, Taiho, and Amgen. Y.C. is a speaker for AbbVie, Bioderma, Galderma, Inova, Eli Lily, Lumenis, Menarini, and Pfizer; an advisory board member for AbbVie, Bayer, Bioderma, CeraVe, Eli Lilly, Menarini, Pfizer, Sanofi, Quanta System, and Janssen. C.-Y.C. is an investigator for AbbVie, Amgen, Dermira, Eli Lilly, Janssen, Novartis, Oneness Biotech, Pfizer, Regeneron Pharmaceuticals Inc., Roche, and Sanofi; a consultant for AbbVie, Amgen, Eli Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, Roche, and Sanofi; a speaker for AbbVie, Eli Lilly, GlaxoSmithKline, Janssen, Mylan, Novartis, Pfizer, Roche, Sanofi, and Viatris; and an advisory board member for AbbVie, Amgen, Mylan, Pfizer, Roche, Sanofi, and Viatris. All other authors have no conflict of interest. Nisha Suyien Chandran has received fees for participation in advisory boards from AbbVie, Johnson and Johnson, Sanofi, Pfizer, DKSH, L’Oreal, and Novartis; investigator fees for clinical trials from AbbVie, Novartis, Amgen, Sanofi, and Boehringer Ingelheim; and speaker honoraria from Galderma, Johnson and Johnson, LEO, Pfizer, Sanofi, and Lion Corporation.

: Ethical approval was received from the following IRBs: Korea University Ansan Hospital, Chulalongkorn University, Father Muller Hospital, NPO MINS, National Taiwan University Hospital, Hong Kong Doctor Union, and Sir Run Run Shaw Hospital. The Parkway Independent Ethics Committee granted an exemption from review. The study was conducted in accordance with the protocol, Guidelines for Good Pharmacoepidemiology Practices, and the Declaration of Helsinki. All participants provided informed consent.